Corporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective - The Views of 240 Patient Groups - ResearchAndMarkets.com
The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - USA Edition - The Views of 240 USA Patient Groups" report has been added to ResearchAndMarkets.com's offering.
- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - USA Edition - The Views of 240 USA Patient Groups" report has been added to ResearchAndMarkets.com's offering.
- Patient groups responding to the 'Corporate Reputation of Pharma' survey are uniquely positioned to comment on the pharma industry's performance during the pandemic.
- The report provides highlights on:
The 240 US patient groups responding to the 2021 survey rated the pharma industry more favourably for corporate reputation than their predecessors in previous years. - 2021's 240 respondent US patient groups registered significant drops in their approval ratings when asked in the 'Corporate Reputation' survey about specific pharma activities of importance to patients and patient groups - especially patient safety, patient centricity, patient information, and integrity.